2024-01-17 06:08:00
the essential Through the DP MetaBreast study, Toulouse researchers want to demonstrate the role of certain atypical cells in the development of breast cancer. Explanations from Professor Florence Dalenc, from the IUCT-Oncopole senology committee.
You are leading the DP MetaBreast study, what is it regarding?
We observe in the blood of patients with different cancers, circulating cells which express both tumor and immune system marks. We speak of double positive (DP) cells. Several scientific data also point out that these cells might be at the origin of the dissemination of the disease and would therefore have a poor prognosis. Through the DP MetaBreast clinical study, we will observe these cells specifically in breast cancer patients to try to demonstrate whether they are indeed derived from tumors. By characterizing them we can then use them as biomarkers to identify new therapeutic targets.
Read also :
Breast cancer: everyone is affected by screening, even before the age of 50!
How will this study take place?
This single-center study will take place only at theIUCT Oncopole and will begin in spring 2024. It will include sixty patients with metastatic breast cancer. In fact, it has been observed that the more advanced the metastatic disease, the more numerous the cells. The protocol will be simple and minimally intrusive, it will consist of a single blood test, without any impact on usual treatment or follow-up. We will then compare for each patient, the tumor biopsy already stored and these circulating cells, in order to check the presence of common markers.
Read also :
More than €500,000 to support cancer research projects in Toulouse
You have received funding from the Toulouse cancer health foundation for this study described as innovative?
In fact, we have obtained funding of 118,300 euros which will help us with the laboratory component. What is innovative in our work is that few teams in the world are interested in these cells, particularly in patients with breast cancer. Furthermore, we will work in partnership with Doctor Frédéric Chibon of Toulouse Cancer Research Center (CRCT) and expand research to other cancers.
1705485524
#Breast #cancer #clinical #study #understand #origin #tumor
